siRNAgen Therapeutics is a clinical-stage biotechnology company revolutionizing precision medicine through our proprietary SAMiRNA™ platform. Founded in 2019 as a spinout from Bioneer Corporation, we leverage two decades of oligonucleotide expertise to develop transformative RNAi therapies for immunology, cancer, and degenerative diseases.
Our mission is to deliver innovative treatments that improve lives by targeting disease at its molecular core. Key highlights include:
Our SAMiRNA™ platform enables precise, safe delivery of siRNA to extrahepatic tissues, such as the lungs and brain, addressing complex diseases like idiopathic pulmonary fibrosis (IPF), cancers, and immune diseases.
Our lead candidate, SRN001, is advancing in clinical trials for IPF, demonstrating our commitment to impactful patient outcomes.
Our team of 20 includes 30% PhD holders, driving innovation with world-class expertise.
We partner with leading academic and industry experts to accelerate the development of next-generation RNAi therapeutics.
At siRNAgen, we are driven by a passion for science and a commitment to patients, working to redefine the future of medicine.